Evidence map›Paper›PMID 20373904›Full record

ReviewJournal of aerosol medicine and pulmonary drug delivery2010

The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.

John Denyer, Tony Dyche

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of aerosol medicine and pulmonary drug delivery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06157515 (Inhaled Dose Analysis Using a Breath Actuated Nebulizer in Healthy Subjects), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06157515 nacompletednot on this mapstarted 2024, after this paper: background citation

Inhaled Dose Analysis Using a Breath Actuated Nebulizer in Healthy Subjects

TypeinterventionalSponsorChang Gung UniversityRan2024 to 2024Enrolled25ConditionsHealthy Volunteers, Aerosol Therapy, Inhaled Drug Dose, Pharmacogenomic Drug InteractionArmsBreath-actuated vibrating mesh nebulizer, Continuous vibrating mesh nebulizer
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Nebuliser systems for drug delivery in cystic fibrosis.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.American journal of respiratory and critical care medicine · 2014
    Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Future Trends in Nebulized Therapies for Pulmonary Disease.Journal of personalized medicine · 2020
    Review
  10. Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.Journal of aerosol medicine and pulmonary drug delivery · 2019
    Review
  11. Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.International journal of molecular sciences · 2017
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. lloprost delivered via the BREELIBTherapeutic advances in respiratory disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

John DenyerPhilips Respironics, Respiratory Drug Delivery Ltd, Chichester, United Kingdom. john.denyer@philips.com
Tony Dyche

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional aerosol delivery systems and the availability of new technologies have led to the development of "intelligent" nebulizers such as the I-neb Adaptive Aerosol Delivery (AAD) System. Based on the AAD technology, the I-neb AAD System has been designed to continuously adapt to changes in the patient's breathing pattern, and to pulse aerosol only during the inspiratory part of the breathing cycle. This eliminates waste of aerosol during exhalation, and creates a foundation for precise aerosol (dose) delivery. To facilitate the delivery of precise metered doses of aerosol to the patient, a unique metering chamber design has been developed. Through the vibrating mesh technology, the metering chamber design, and the AAD Disc function, the aerosol output rate and metered (delivered) dose can be tailored to the demands of the specific drug to be delivered. In the I-neb AAD System, aerosol delivery is guided through two algorithms, one for the Tidal Breathing Mode (TBM), and one for slow and deep inhalations, the Target Inhalation Mode (TIM). The aim of TIM is to reduce the treatment time by increasing the total inhalation time per minute, and to increase lung deposition by reducing impaction in the upper airways through slow and deep inhalations. A key feature of the AAD technology is the patient feedback mechanisms that are provided to guide the patient on delivery performance. These feedback signals, which include visual, audible, and tactile forms, are configured in a feedback cascade that leads to a high level of compliance with the use of the I-neb AAD System. The I-neb Insight and the Patient Logging System facilitate a further degree of sophistication to the feedback mechanisms, by providing information on long term adherence and compliance data. These can be assessed by patients and clinicians via a Web-based delivery of information in the form of customized graphical analyses.

Indexed as

Administration, InhalationAerosolsAlgorithmsDrug Delivery SystemsEquipment DesignHumansMedication AdherenceNebulizers and VaporizersPharmaceutical PreparationsRespiratory MechanicsTechnology, PharmaceuticalTime FactorsAerosolsPharmaceutical Preparations

Identifiers

PMID20373904
PMCPMC3116630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.